Read + Share

Amedeo Smart

Independent Medical Education


Read + Share

Mirza MR, Bergmann TK, Mau-Sorensen M, Christensen RD, et al. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. Cancer Chemother Pharmacol 2019 Aug 2. pii: 10.1007/s00280-019-03917.
PMID: 31375879


Free Medical Abstracts
Privacy Policy
Sponsors
Share
About

© Amedeo 1997-2016